Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL23566696 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL28953943 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL409772 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL28359238 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Water SCHEMBL29706462 | 0.98 | LMNA (0.83) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL24132 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL20547381 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL16180766 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL23415272 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL29661854 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458093-A1 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | Karl, Christoph (CH) | 2019-03-27 | — | — | EP | disclosed |
| EP-1365768-B1 | USE OF ER-BETA SELECTIVE ANTAGONISTS AS CONTRACEPTIVES | BAYER SCHERING PHARMA AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6794409-B2 | HOMOSTEROIDS SUCH AS 17-CHLORO-17A-ALPHA-ETHINYL-17A, 18A-DIHOMO-ESTRA-1,3,5(10),16-TETRAENE-3,17A BETA-DIOL; WITHOUT USE OF PROGESTIN; CONTRACEPTION; FOR TREATMENT OF PROLIFERATIVE DISEASES OF THE OVARY | SCHERING AG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1365768-A2 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | Schering Aktiengesellschaft (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2002068548-A9 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | SCHERING AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002068548-A1 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | SCHERING AG (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESRRB, ESR2 | LMNA 4408/4885PDE4A 1614/4885L3MBTL1 1719/4885 |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESR2, ESRRB | LMNA 4313/4885PDE4A 1941/4885L3MBTL1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.